Search Results

1 - 7 of 7 items :

  • "vortioxetine" x
Clear All
Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results

References [1] Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014;10:1297–1307. [2] Farsky I, Smetanka A, Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441. [3] Nemeroff CB. Prevalence and management of treatment resistant depression. J Clin Psychiatry. 2007;68(Suppl 8):17–25. [4] Serreti A, Chiesa A. Treatment-emergent sexual dysfunction

Open access
Review of a New Multimodal Antidepressant Vortioxetine

REFERENCES 1. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014; 10: 1297-1307. 2. Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003; 12 (3): 165. 3. Farsky I, Smetanka A, Dubinska S. Spirituality of patients with selected psychiatric disorders

Open access
Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine

References [1] Alonso J, Angermeyer MC, Bernert S et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. ActaPsychiatrSc and Suppl. 2004;420:21-27. [2] Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014;10:1297-1307. [3] Baldwin DS, Serenko M, Palo W, Lophaven S, Matz J. The safety and tolerability of

Open access
Antidepressant effects of valproic acid in an animal model of depression

] Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 82:332-338. [5] Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol. 2012;15(2):247-65. [6

Open access
Low molecular mass chondroitin sulfate suppresses chronic unpredictable mild stress-induced depression-like behavior in mice

prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment, Psychopharmacology (Berlin) 233 (2016) 3259–3267; https://doi.org/10.1007/s00213-016-4364-0 15. Y. Zhang, F. Gu, J. Chen and W. Dong, Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat, Brain Res. 1366 (2010) 141–148; https://doi.org/10.1016/j.brainres.2010.09.095

Open access
The Antidepressants and the Metabolic Syndrome

. Stahl’s Essential Psychopharmacology. Forth Edit. Cambridge University Press; 2013; 284-346. 39. Kahl KG, Westhoff-Bleck M, Krüger THC. Effects of psychopharmacological treatment with antidepressants on the vascular system. Vascul. Pharmacol. 2017;96–98:11–8. 40. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol. Ther. Pergamon; 2015;145:43–57. 41. Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of

Open access
Immunological Aspects of Depressive Disorder – The Review

vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:1297-307. 5. Elomaa AP, Niskanen L, Herzig KH, Viinamäki H, Hintikka J, Koivumaa-Honkanen H, et al. Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC Psychiatry 2012;12:2. 6. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201–17. 7. Dantzer R, Bluthe RM, Ghensi G, Cremona S, Laye S, Parnet P, et al. Ann. N Y Acad. Sci. 1998;856, 132

Open access